BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: BioMarin issued EPS guidance of $4.85–$5.05 (consensus $4.98) and revenue guidance of $3.8–$3.9 billion (consensus $3.7 billion).
• Recent results and market reaction: Q1 EPS was $0.76 (miss) while revenue was $766.2M (beat); the stock rose about 2.6% to $55.46 and analysts retain a Moderate Buy consensus with an average target of $91.48.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 4.850-5.05 for the period, compared to the consensus EPS estimate of 4.980. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.7 billion.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BMRN shares. Jefferies Financial Group restated a "buy" rating and set a $103.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, March 12th. Morgan Stanley started coverage on shares of BioMarin Pharmaceutical in a research report on Monday, April 27th. They set an "overweight" rating and a $120.00 target price on the stock. Barclays raised their target price on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 3rd. Stifel Nicolaus set a $68.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, February 24th. Finally, Canaccord Genuity Group raised their target price on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $91.48.

BioMarin Pharmaceutical Trading Up 2.6%

NASDAQ BMRN traded up $1.40 during mid-day trading on Monday, reaching $55.46. 2,807,634 shares of the stock were exchanged, compared to its average volume of 2,013,365. BioMarin Pharmaceutical has a 1-year low of $50.76 and a 1-year high of $66.28. The business's fifty day simple moving average is $56.93 and its 200 day simple moving average is $56.32. The stock has a market capitalization of $10.72 billion, a PE ratio of 31.16, a PEG ratio of 0.54 and a beta of 0.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The biotechnology company reported $0.76 earnings per share for the quarter, missing analysts' consensus estimates of $0.94 by ($0.18). The company had revenue of $766.21 million during the quarter, compared to analyst estimates of $752.15 million. BioMarin Pharmaceutical had a net margin of 10.83% and a return on equity of 7.91%. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.850-5.05 EPS. On average, research analysts anticipate that BioMarin Pharmaceutical will post 4.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total value of $996,743.56. Following the transaction, the executive vice president owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares in the company, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently made changes to their positions in BMRN. CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at $40,000. Parallel Advisors LLC boosted its holdings in shares of BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 1,974.1% in the 4th quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company's stock valued at $105,000 after purchasing an additional 1,678 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at $201,000. Institutional investors and hedge funds own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.